# EDGAR Filing Document

**Accession Number:** 0001576885
**File Stem:** 0000000000-26-003177
**Filing Date:** 2026-3
**Character Count:** 2267
**Document Hash:** 712449780170ad68df668688d1c73366
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-003177.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0000000000-26-003177

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260330

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acumen Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001576885
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 364108129
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-294649

**BUSINESS ADDRESS:**
- **STREET 1:** 1210-1220 WASHINGTON STREET
- **STREET 2:** SUITE 210
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02465
- **BUSINESS PHONE:** 617-344-4190

**MAIL ADDRESS:**
- **STREET 1:** 1210-1220 WASHINGTON STREET
- **STREET 2:** SUITE 210
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02465
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001628280-26-021442

## Text-Extract

```

                                                           March 30, 2026

Daniel O'Connell
Chief Executive Officer
Acumen Pharmaceuticals, Inc.
1210-1220 Washington Street, Suite 210
Newton, Massachusetts 02465

       Re: Acumen Pharmaceuticals, Inc.
           Registration Statement on Form S-3
           Filed March 26, 2026
           File No. 333-294649
Dear Daniel O'Connell:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tim Buchmiller at 202-551-3635 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Thomas J. Danielski, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._